| October 1, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| October 1, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| October 1, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| October 1, 2026 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| October 1, 2026 |
NVO |
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation |
Trial Milestone |
Phase 3 |
| October 1, 2026 |
ARGX |
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia |
Trial Milestone |
Phase 3 |
| October 1, 2026 |
VIR |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| October 1, 2026 |
NKTR |
8-K filed: Reg FD disclosure |
Filing |
— |
| October 1, 2026 |
SGP |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| October 1, 2026 |
NVCR |
8-K filed: Reg FD disclosure |
Filing |
— |
| October 1, 2026 |
KYNB |
8-K filed: Leadership change |
Corporate |
— |
| October 1, 2026 |
CATX |
8-K filed: Other event |
Filing |
— |
| October 1, 2026 |
SGMT |
8-K filed: Material agreement |
Corporate |
— |
| October 1, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| October 1, 2026 |
ACHV |
8-K filed: Leadership change |
Corporate |
— |
| October 1, 2026 |
LTRN |
8-K filed: Listing / standard notice |
Corporate |
— |
| October 1, 2026 |
DRUG |
6-K filed: Foreign issuer report |
Filing |
— |
| October 2, 2026 |
AZN |
6-K filed: Corporate announcement |
Corporate |
— |
| October 2, 2026 |
TEVA |
A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease |
Trial Milestone |
Phase 2 |
| October 2, 2026 |
LNTH |
8-K filed: Other event |
Filing |
— |
| October 2, 2026 |
BYSI |
8-K filed: Listing / standard notice |
Corporate |
— |
| October 2, 2026 |
ACIU |
6-K filed: Foreign issuer report |
Filing |
— |
| October 2, 2026 |
CNSY |
Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases |
Trial Milestone |
Phase 1/Phase 2 |
| October 2, 2026 |
CNSY |
8-K filed: Other event |
Filing |
— |
| October 2, 2026 |
DRUG |
6-K filed: Foreign issuer report |
Filing |
— |
| October 2, 2026 |
BIOA |
8-K filed: Other event |
Filing |
— |
| October 2, 2026 |
CGEM |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| October 5, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| October 5, 2026 |
ABBV |
Quarterly results filed (8-K) |
Earnings |
— |
| October 5, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| October 5, 2026 |
MRNA |
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults |
Trial Milestone |
Phase 1/Phase 2 |
| October 5, 2026 |
INSM |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| October 5, 2026 |
IOVA |
8-K filed: Other event |
Filing |
— |
| October 5, 2026 |
PCVX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| October 5, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| October 5, 2026 |
COYA |
8-K filed: Other event |
Filing |
— |
| October 5, 2026 |
IMNM |
8-K filed: Material agreement |
Corporate |
— |
| October 5, 2026 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| October 6, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| October 6, 2026 |
REGN |
Quarterly results filed (8-K) |
Earnings |
— |
| October 6, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| October 6, 2026 |
BMRN |
Quarterly results filed (8-K) |
Earnings |
— |
| October 6, 2026 |
AVBP |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| October 6, 2026 |
MAIA |
8-K filed: Reg FD disclosure |
Filing |
— |
| October 6, 2026 |
KYNB |
8-K filed: Listing / standard notice |
Corporate |
— |
| October 6, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| October 6, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| October 6, 2026 |
BYSI |
8-K filed: Acquisition completed |
Corporate |
— |
| October 6, 2026 |
SXTP |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| October 7, 2026 |
AZN |
A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES) |
Trial Milestone |
Phase 1/Phase 2 |
| October 7, 2026 |
REGN |
Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD) |
Trial Milestone |
Phase 3 |
| October 7, 2026 |
RARE |
8-K filed: Material agreement |
Corporate |
— |
| October 7, 2026 |
BSX |
8-K filed: Leadership change, Other event |
Corporate |
— |
| October 7, 2026 |
SYRE |
8-K filed: Material agreement |
Corporate |
— |
| October 7, 2026 |
TTRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| October 7, 2026 |
LPCN |
8-K filed: Other event |
Filing |
— |
| October 8, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| October 8, 2026 |
ARGX |
6-K filed: Foreign issuer report |
Filing |
— |
| October 8, 2026 |
VIR |
8-K filed: Other event |
Filing |
— |
| October 8, 2026 |
VTRS |
8-K filed: Material agreement, Other event |
Corporate |
— |
| October 8, 2026 |
TENX |
8-K filed: Other event |
Filing |
— |
| October 8, 2026 |
PCRX |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| October 8, 2026 |
ANGO |
Quarterly results filed (8-K) |
Earnings |
— |
| October 8, 2026 |
ANGO |
8-K filed: Material agreement, Leadership change |
Corporate |
— |
| October 8, 2026 |
CATX |
8-K filed: Other event |
Filing |
— |
| October 8, 2026 |
VALN |
6-K filed: Foreign issuer report |
Filing |
— |
| October 8, 2026 |
XFOR |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| October 8, 2026 |
EDIT |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| October 9, 2026 |
INCY |
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) |
Trial Milestone |
Phase 3 |
| October 9, 2026 |
INCY |
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) |
Trial Milestone |
Phase 3 |
| October 9, 2026 |
JAZZ |
8-K filed: Leadership change |
Corporate |
— |
| October 9, 2026 |
PCVX |
8-K filed: Material agreement, Other event |
Corporate |
— |
| October 9, 2026 |
VTGN |
8-K filed: Leadership change |
Corporate |
— |
| October 9, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| October 9, 2026 |
MBRX |
8-K filed: Leadership change |
Corporate |
— |
| October 12, 2026 |
BMY |
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma |
Trial Milestone |
Phase 1/Phase 2 |
| October 12, 2026 |
JNJ |
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC |
Trial Milestone |
Phase 3 |
| October 12, 2026 |
REGN |
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment |
Trial Milestone |
Phase 3 |
| October 13, 2026 |
MRK |
8-K filed: Leadership change |
Corporate |
— |
| October 13, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| October 13, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| October 13, 2026 |
JNJ |
Quarterly results filed (8-K) |
Earnings |
— |
| October 13, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| October 13, 2026 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| October 13, 2026 |
RVMD |
8-K filed: Other event |
Filing |
— |
| October 13, 2026 |
INBS |
8-K filed: Reg FD disclosure |
Filing |
— |
| October 13, 2026 |
MRNA |
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants |
Trial Milestone |
Phase 1 |
| October 13, 2026 |
MIRM |
8-K filed: Other event |
Filing |
— |
| October 13, 2026 |
ZBIO |
8-K filed: Reg FD disclosure |
Filing |
— |
| October 13, 2026 |
AVBP |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| October 13, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| October 13, 2026 |
NRIX |
Quarterly results filed (8-K) |
Earnings |
— |
| October 13, 2026 |
OTLC |
8-K filed: Other event |
Filing |
— |
| October 13, 2026 |
ONCY |
8-K filed: Other event |
Filing |
— |
| October 13, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| October 13, 2026 |
ILMN |
8-K filed: Material agreement |
Corporate |
— |
| October 14, 2026 |
MRK |
A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039) |
Trial Milestone |
Phase 1 |
| October 14, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| October 14, 2026 |
SNY |
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps |
Trial Milestone |
Phase 3 |
| October 14, 2026 |
RARE |
8-K filed: Material agreement |
Corporate |
— |
| October 14, 2026 |
KPTI |
8-K filed: Other event |
Filing |
— |
| October 14, 2026 |
QNRX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| October 14, 2026 |
VSTM |
Quarterly results filed (8-K) |
Earnings |
— |
| October 14, 2026 |
PHAR |
6-K filed: Foreign issuer report |
Filing |
— |
| October 14, 2026 |
LQDA |
8-K filed: Material agreement, Reg FD disclosure, Other event |
Corporate |
— |
| October 14, 2026 |
VIR |
8-K filed: Other event |
Filing |
— |
| October 14, 2026 |
UTHR |
8-K filed: Other event |
Filing |
— |
| October 14, 2026 |
ONCY |
8-K filed: Other event |
Filing |
— |
| October 14, 2026 |
COYA |
8-K filed: Other event |
Filing |
— |
| October 14, 2026 |
TRDA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| October 14, 2026 |
AKBA |
8-K filed: Leadership change |
Corporate |
— |
| October 15, 2026 |
LLY |
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function |
Trial Milestone |
Phase 1 |
| October 15, 2026 |
LLY |
A Study of Eloralintide (LY3841136) in Healthy Participants |
Trial Milestone |
Phase 1 |
| October 15, 2026 |
LLY |
A Study of LY4268989 (MORF 057) in Healthy Participants |
Trial Milestone |
Phase 1 |
| October 15, 2026 |
LLY |
A Study of LY3867070 in Healthy Participants |
Trial Milestone |
Phase 1 |
| October 15, 2026 |
ABBV |
A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult Participants |
Trial Milestone |
Phase 2 |
| October 15, 2026 |
INCY |
A Study to Assess the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB161734 in Healthy Male Participants |
Trial Milestone |
Phase 1 |
| October 15, 2026 |
BNTX |
A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions |
Trial Milestone |
Phase 1 |
| October 15, 2026 |
VNDA |
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension |
Trial Milestone |
Phase 2 |
| October 15, 2026 |
IBRX |
A Study to Assess Anktiva in Patients With Long Covid-19. |
Trial Milestone |
Phase 2 |
| October 15, 2026 est. |
ALNY |
Next quarterly earnings (projected) |
Earnings |
— |
| October 15, 2026 |
MIRM |
Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) |
Trial Milestone |
Phase 3 |
| October 15, 2026 est. |
NUVB |
Next quarterly earnings (projected) |
Earnings |
— |
| October 15, 2026 |
XENE |
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder |
Trial Milestone |
Phase 3 |
| October 15, 2026 |
EYPT |
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 |
Trial Milestone |
Phase 3 |
| October 15, 2026 |
IDYA |
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors |
Trial Milestone |
Phase 1 |
| October 15, 2026 |
CLDX |
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria |
Trial Milestone |
Phase 3 |
| October 15, 2026 |
CLDX |
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) |
Trial Milestone |
Phase 3 |
| October 15, 2026 |
IMVT |
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE) |
Trial Milestone |
Phase 2 |
| October 15, 2026 |
VTRS |
A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Chinese Adults With Chronic Coronary Syndrome |
Trial Milestone |
Phase 1 |
| October 15, 2026 est. |
CADL |
Next quarterly earnings (projected) |
Earnings |
— |
| October 15, 2026 |
CORT |
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis |
Trial Milestone |
Phase 2 |
| October 15, 2026 |
IMCR |
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors |
Trial Milestone |
Phase 1/Phase 2 |
| October 15, 2026 est. |
IMCR |
Next quarterly earnings (projected) |
Earnings |
— |
| October 15, 2026 |
SLDB |
Microdystrophin Gene Transfer Study in Adolescents and Children With DMD |
Trial Milestone |
Phase 1/Phase 2 |
| October 15, 2026 est. |
TNGX |
Next quarterly earnings (projected) |
Earnings |
— |
| October 15, 2026 est. |
BEAM |
Next quarterly earnings (projected) |
Earnings |
— |
| October 15, 2026 est. |
LXEO |
Next quarterly earnings (projected) |
Earnings |
— |
| October 15, 2026 est. |
ARDX |
Next quarterly earnings (projected) |
Earnings |
— |
| October 15, 2026 |
BCRX |
A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725 |
Trial Milestone |
Phase 1 |
| October 15, 2026 |
OGN |
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects |
Trial Milestone |
Phase 3 |
| October 15, 2026 |
IRON |
Study of DISC-0974-201 in Participants With IBD and Anemia |
Trial Milestone |
Phase 2 |
| October 16, 2026 est. |
MRNA |
Next quarterly earnings (projected) |
Earnings |
— |
| October 16, 2026 est. |
VIR |
Next quarterly earnings (projected) |
Earnings |
— |
| October 16, 2026 est. |
SPRB |
Next quarterly earnings (projected) |
Earnings |
— |
| October 17, 2026 est. |
TVTX |
Next quarterly earnings (projected) |
Earnings |
— |
| October 17, 2026 est. |
BFRI |
Next quarterly earnings (projected) |
Earnings |
— |
| October 19, 2026 |
AZN |
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics |
Trial Milestone |
Phase 4 |
| October 19, 2026 |
BMY |
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus |
Trial Milestone |
Phase 3 |
| October 19, 2026 |
INCY |
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants |
Trial Milestone |
Phase 1 |
| October 19, 2026 |
INCY |
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) |
Trial Milestone |
Phase 3 |
| October 19, 2026 |
INCY |
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) |
Trial Milestone |
Phase 3 |
| October 19, 2026 est. |
AXSM |
Next quarterly earnings (projected) |
Earnings |
— |
| October 19, 2026 est. |
AVIR |
Next quarterly earnings (projected) |
Earnings |
— |
| October 19, 2026 est. |
ERAS |
Next quarterly earnings (projected) |
Earnings |
— |
| October 20, 2026 |
BIIB |
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus |
Trial Milestone |
Phase 2/Phase 3 |
| October 20, 2026 est. |
KURA |
Next quarterly earnings (projected) |
Earnings |
— |
| October 21, 2026 est. |
ALMS |
Next quarterly earnings (projected) |
Earnings |
— |
| October 21, 2026 est. |
ACRV |
Next quarterly earnings (projected) |
Earnings |
— |
| October 22, 2026 est. |
PRAX |
Next quarterly earnings (projected) |
Earnings |
— |
| October 22, 2026 est. |
KPTI |
Next quarterly earnings (projected) |
Earnings |
— |
| October 22, 2026 est. |
IVVD |
Next quarterly earnings (projected) |
Earnings |
— |
| October 22, 2026 est. |
QURE |
Next quarterly earnings (projected) |
Earnings |
— |
| October 22, 2026 est. |
GOSS |
Next quarterly earnings (projected) |
Earnings |
— |
| October 22, 2026 est. |
WST |
Next quarterly earnings (projected) |
Earnings |
— |
| October 22, 2026 est. |
ILMN |
Next quarterly earnings (projected) |
Earnings |
— |
| October 23, 2026 est. |
CLRB |
Next quarterly earnings (projected) |
Earnings |
— |
| October 23, 2026 est. |
KYTX |
Next quarterly earnings (projected) |
Earnings |
— |
| October 24, 2026 est. |
NBIX |
Next quarterly earnings (projected) |
Earnings |
— |
| October 25, 2026 est. |
RARE |
Next quarterly earnings (projected) |
Earnings |
— |
| October 26, 2026 est. |
TYRA |
Next quarterly earnings (projected) |
Earnings |
— |
| October 26, 2026 est. |
PGEN |
Next quarterly earnings (projected) |
Earnings |
— |
| October 27, 2026 est. |
INCY |
Next quarterly earnings (projected) |
Earnings |
— |
| October 27, 2026 est. |
CORT |
Next quarterly earnings (projected) |
Earnings |
— |
| October 28, 2026 |
AZN |
Investigating the Effect of Itraconazole on the Pharmacokinetics of AZD4144 in Healthy Participants |
Trial Milestone |
Phase 1 |
| October 28, 2026 est. |
EXEL |
Next quarterly earnings (projected) |
Earnings |
— |
| October 28, 2026 est. |
TEVA |
Next quarterly earnings (projected) |
Earnings |
— |
| October 28, 2026 est. |
BSX |
Next quarterly earnings (projected) |
Earnings |
— |
| October 28, 2026 est. |
CMPS |
Next quarterly earnings (projected) |
Earnings |
— |
| October 28, 2026 est. |
MPLT |
Next quarterly earnings (projected) |
Earnings |
— |
| October 29, 2026 |
NVS |
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) |
Trial Milestone |
Phase 3 |
| October 29, 2026 est. |
BMY |
Next quarterly earnings (projected) |
Earnings |
— |
| October 29, 2026 est. |
AGIO |
Next quarterly earnings (projected) |
Earnings |
— |
| October 29, 2026 |
MRNA |
Q3 2026 Earnings |
Earnings |
— |
| October 29, 2026 est. |
MDGL |
Next quarterly earnings (projected) |
Earnings |
— |
| October 29, 2026 est. |
BCYC |
Next quarterly earnings (projected) |
Earnings |
— |
| October 29, 2026 est. |
SGP |
Next quarterly earnings (projected) |
Earnings |
— |
| October 29, 2026 est. |
LXRX |
Next quarterly earnings (projected) |
Earnings |
— |
| October 30, 2026 |
AZN |
Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease |
Trial Milestone |
Phase 4 |
| October 30, 2026 |
JNJ |
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies |
Trial Milestone |
Phase 1 |
| October 30, 2026 |
CORT |
Evaluating the Pharmacokinetics and Safety of Miricorilant |
Trial Milestone |
Phase 1 |
| October 30, 2026 est. |
TENX |
Next quarterly earnings (projected) |
Earnings |
— |
| October 30, 2026 |
MBX |
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity |
Trial Milestone |
Phase 1 |
| October 30, 2026 est. |
STOK |
Next quarterly earnings (projected) |
Earnings |
— |
| October 30, 2026 est. |
CNSY |
Next quarterly earnings (projected) |
Earnings |
— |
| October 30, 2026 |
ILMN |
18F-mFBG Imaging for Myocardial Sympathetic Innervation |
Trial Milestone |
Phase 2 |
| October 30, 2026 |
ILMN |
18F-mFBG Cardiac Uptake With Lewy Body Dementia |
Trial Milestone |
Phase 2 |
| October 31, 2026 |
AZN |
Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients |
Trial Milestone |
Phase 4 |
| October 31, 2026 |
TAK |
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer |
Trial Milestone |
Phase 1/Phase 2 |
| October 31, 2026 |
ONC |
A Study to Investigate the Effect of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-58067 in Healthy Participants |
Trial Milestone |
Phase 1 |
| October 31, 2026 |
TGTX |
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS) |
Trial Milestone |
Phase 3 |
| October 31, 2026 |
TEVA |
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations |
Trial Milestone |
Phase 3 |
| October 31, 2026 |
REPL |
Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors |
Trial Milestone |
Phase 1 |
| October 31, 2026 |
SRPT |
A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON) |
Trial Milestone |
Phase 3 |
| October 31, 2026 |
RYTM |
A Study of Setmelanotide in Patients With Prader-Willi Syndrome |
Trial Milestone |
Phase 2 |
| October 31, 2026 est. |
PVLA |
Next quarterly earnings (projected) |
Earnings |
— |
| October 31, 2026 est. |
IRD |
Next quarterly earnings (projected) |
Earnings |
— |
| October 31, 2026 |
OLMA |
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer |
Trial Milestone |
Phase 3 |
| October 31, 2026 est. |
VTVT |
Next quarterly earnings (projected) |
Earnings |
— |
| October 31, 2026 |
SYRE |
A Study of SPY072 in Rheumatic Disease |
Trial Milestone |
Phase 2 |
| October 31, 2026 est. |
HALO |
Next quarterly earnings (projected) |
Earnings |
— |